65,437 trials
Gastroenteropancreatic Neuroendocrine Tumor
Primary: Clinical Benefit Rate (CBR) of Tumour Response Assessed by Blinded Independent Central Review (BICR) at Week 24 — 62.79 percentage of participants
Diabetic Foot Ulcer
Primary: Number of Participants With Complete (100%) Wound Closure Defined as Complete Re-epithelialization Without Drainage — 24; 12 Participants
Diabetes · Myocardial Infarction
Primary: Primary Composite Outcome — 85; 89; 90; 86 Participants
Renal Cell Cancer · Renal Cell Carcinoma · Cancer of Kidney
Primary: Number of Participants According to Co-Diagnoses Before Index — 139; 45; 41; 26 Participants
Healthy
Primary: Area Under the Serum Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Unbound and Total Ponsegromab — 109000; 590200; 350300; 1105000…
Pneumococcal Infections
Primary: Immune Responses — 1.95; 1.69; 1.22; 0.78 ug/mL
Ocular Hypertension · Open Angle Glaucoma
Primary: Ocular Treatment Emergent Adverse Events — 9; 7; 9; 1 Number of Treatment-Emergent Events
COVID-19
Primary: COVID-19 Testing — 378; 400 Participants
Idiopathic Pulmonary Fibrosis
Primary: Total All-cause Medical Costs — 12647.73; 13580.61; 17549.74; 15375.10 United States dollars — p=0.516
Pemphigus Vulgaris · Pemphigus Foliaceus
Primary: Number of Pemphigus Vulgaris (PV) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy — 44; 20 Participants
Colorectal Cancer · Advanced Adenocarcinoma · Serrated Polyp
Primary: ColoSense Sensitivity for Colorectal Cancer (CRC) — 25; 2 Participants
Prostate Adenocarcinoma
Primary: Biochemical Disease-Free Survival (bDFS), Using Phoenix and ASTRO Definitions — 46; 27; 45; 27 Participants
Cystic Fibrosis
Primary: Absolute Change in FEV1 % Predicted From Week 0 to Week 6 — -0.2; 0.1 FEV1 % predicted — p=<0.0001
Arthritis, Rheumatoid
Primary: Duration of Tofacitinib Drug Survival — 26.4 Months
Migraine · Headache
Primary: 30 Minute Pain Score — 3; 3; 3 score on a scale